Evoglip- M
Composition: Sitagliptin 50 mg + Metformin 500 mg
Evoglip M5 is a combination anti-diabetic tablet containing Sitagliptin 50 mg and Metformin 500 mg. This dual therapy provides comprehensive sugar control: Metformin reduces liver glucose output and improves insulin sensitivity, while Sitagliptin enhances incretin activity for better post-meal insulin response. Evoglip M500 is commonly prescribed for patients whose blood sugar is not controlled with Metformin alone.
Uses:
- Type 2 Diabetes control
- Significant HbA1c reduction
- Better post-meal sugar control
- Helps in insulin regulation
Side Effects:
- Nausea, diarrhea, stomach upset (Metformin-related)
- Headache
- Respiratory infections
- Rare: lactic acidosis or pancreatitis
Other Details:
- Best taken with meals to avoid gastric issues
- Not recommended in severe kidney disease
- Supports weight maintenance
